about
Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's diseaseHuman neoplasms elicit multiple specific immune responses in the autologous hostA testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningHuman carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancersMutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondTranslation of genomics-guided RNA-based personalised cancer vaccines: towards the bedsideSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapyOpposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sourcesThe SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinomaIdentification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity.A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing.SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity.Definition of tumor-associated antigens in hepatocellular carcinoma.Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein.Molecular characterization of virus-induced autoantibody responses.Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.HLA typing from RNA-Seq sequence readsSynthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.Confidence-based somatic mutation evaluation and prioritizationAntigen identification using SEREX.Autoimmunity seen through the SEREX-scope.A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell linesSpecific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosisTCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expressionCXorf61 is a target for T cell based immunotherapy of triple-negative breast cancerMutant MHC class II epitopes drive therapeutic immune responses to cancer.Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.Selective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2.Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.Synthetic mRNAs with superior translation and stability properties.Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.mRNA-based therapeutics--developing a new class of drugs.Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.Mutanome directed cancer immunotherapy.Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.
P50
Q24322331-474982C3-B0C6-43D1-A257-16BA48567DE8Q24564371-51FB2A8B-F280-414C-9393-A367EB299F6DQ24564781-A9754AC1-C798-41A7-A07A-75CEA1898AECQ24651144-2DA2FEE5-544D-437E-A7E4-520BEF55EA44Q26769044-8A371A8B-9DCA-4C9F-A925-2122D4F98960Q26861563-5F849EBD-88C2-4A68-B11A-8FE046D72FD3Q27015695-D79CB649-2A35-44BA-B149-D9C8C5C68784Q28005535-7EC5BA08-5A42-4367-981C-D52DFA23F69AQ28287169-E8453401-5E97-461A-A7E9-658F870F0D3AQ28292213-85CBCF19-91EF-4736-AE31-6D8FB2BA1200Q28301765-5F03DE90-5E25-4797-92C6-BDF9A38DCB53Q30357239-DEBFEB8E-158E-40EA-8923-BF974FBB8D1FQ30378994-214C4FF7-AF1C-4F4B-8651-9708F6355144Q30485327-CB6620B5-24CA-4E17-B574-901C64D0A365Q30747135-52EF92E9-2E65-49A1-BB93-8CD92DD87854Q30854839-7BF275B2-B5F1-4815-A673-B83FB9FE18C0Q30916021-36645F78-2928-4E72-AEB2-121F60DF7824Q31092656-6FC243C5-D900-449B-93DA-63B49294727AQ31110185-94097126-C4EE-4008-9870-23D8F2CEC130Q33556731-099406B5-3ECD-4564-B029-66AEE58DEFF3Q33781090-284BD6BE-24D1-4BC8-860B-077F4BAFE4CCQ34249684-B58FC427-0B00-4B85-9F5D-93C22692F593Q34426398-E9610F66-E72A-424E-951B-DE3D3EEEF819Q34960092-84FE5959-B993-4BC8-BBAB-D987397B756CQ35556355-A8BA195D-F794-4DFE-A699-C5B3C2F34BC5Q35626593-84E3C43A-6113-4FC1-B119-776C17317374Q36108921-A853C625-ECCE-4C41-8B7C-8DA9DBC9DA56Q36301828-4334E991-9F09-4B68-A4C2-C424522AD4B1Q36413180-FE23F731-4B36-4998-9245-BD67FA12061BQ36817092-F3B83696-BBB6-40D0-B9F4-64EAC7193B94Q36821083-B7C4FC8D-6426-491F-A345-C19EDE9AFA51Q37225251-A8EE9E52-4DB9-40D0-84C1-056C87C616C1Q37431092-CF1A86E0-D93A-4967-9B7D-FD5F24962C1FQ37671730-2521C7E8-3BDE-4C3B-B9DD-56A4487A6BE4Q38072371-36A66ACB-F939-42E8-B748-E0564B38C851Q38072381-5B5C3FBD-D700-4BB0-BD79-6EC4C96D941DQ38252360-1E70DA29-A216-4668-833B-9561EEBEFD4FQ38422320-21FA2322-49B4-4A21-B78F-A6FBCC06B257Q38682923-24C55369-1C51-4A73-819E-E67F767E58E0Q38779887-EB68074A-13BC-4866-83C8-F679B8944B1B